EGFR and glioblastoma: These results confirm and extend on previous observations by our [20–22] and other groups [40, 41] which indicate that EGFR is the most frequently amplified oncogene in GBM, where it is detected in up to 40% of primary GBM tumors in association with a better outcome, compared to cases that show either no gene amplification or amplification of genes other than EGFR [20, 37].